Skip to main content

Concert Pharmaceuticals, Inc.

CNCEDelisted Mar 6, 2023
Industry
Pharmaceutical Preparations
SEC CIK
0001367920

Concert Pharmaceuticals, Inc. was delisted on Mar 6, 2023; its insiders filed their last Form 4 on Mar 6, 2023; 85 institutions reported holding it in 13F filings for Q4 2022, worth $207.2M in total; no superinvestor held it.

Holders of 5% or more of CNCE

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Concert Pharmaceuticals, Inc., largest stake first. The change is against the holder's previous filing.

No holder currently reports owning 5% or more of Concert Pharmaceuticals, Inc. on Schedule 13D or 13G.

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

11 Schedule 13D and 13G filings on Concert Pharmaceuticals, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on CNCE
Filed (ET)FilerFormStakeChangeEvent dateFiling
Feb 14, 2022Perceptive Advisors LLC13G/AOld format–––SEC
Feb 14, 2022Ra Capital Management, L.P.13G/AOld format–––SEC
Jan 13, 2022Bank of America Corp13G/AOld format–––SEC
Nov 15, 2021Biotechnology Value Fund L P13GOld format–New–SEC
Jul 12, 20218:29 AM ETBlackRock Inc.13G/AOld format–––SEC
Feb 16, 2021Perceptive Advisors LLC13G/AOld format–––SEC
Feb 16, 2021Ra Capital Management, L.P.13GOld format–New–SEC
Feb 12, 2021Dimensional Fund Advisors LP13G/AOld format–––SEC
Feb 9, 2021Ingalls & Snyder LLC13G/AOld format–––SEC
Feb 8, 20215:06 PM ETBank of America Corp13G/AOld format–––SEC
Feb 2, 20212:56 PM ETBlackRock Inc.13GOld format–New–SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Concert Pharmaceuticals, Inc. shares.

No Form 144 notices for Concert Pharmaceuticals, Inc. are on file.